The EPS miss is material, but the pending BSX acquisition at a premium likely provides a floor. Monitor for regulatory updates on the deal close; any delay or termination risk would expose the stock to the full EPS miss. The lack of guidance removes a typical catalyst, making the stock a binary bet on deal completion.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $321.19entry
- T+1 · 4mo ago +0.57%α −0.85% · $323.02
- T+5 · 3mo ago +1.08%α −2.43% · $324.66
- T+20 · 3mo ago +0.15%α −2.84% · $321.68
- T+60 · 22d ago +1.25%α −1.20% · $325.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Penumbra reported Q2 2026 revenue of $390.0M (+14.9% YoY), in line with consensus, but EPS of $0.88 (diluted) missed the $1.18 consensus estimate by 25.4%. The company is not providing guidance due to the pending acquisition by Boston Scientific (BSX), which introduces deal-closing risk and removes the typical earnings catalyst. The EPS miss is significant, but the acquisition premium likely caps downside.
Key Financial Metrics
Key Facts
- Revenue of $390.0M, +14.9% YoY, in line with $390.1M consensus
- Diluted EPS of $0.88, missed consensus of $1.18 by 25.4%
- Net income of $34.8M, down from $45.3M in Q2 2025
- Global thrombectomy revenue $259.0M (+12.5% YoY); embolization & access $131.1M (+20.0% YoY)
- Gross margin improved 190bps to 67.9%
- Operating expenses rose 22.2% YoY, including $6.9M in acquisition-related costs
- No FY2026 guidance provided due to pending Boston Scientific acquisition
- Cash & investments of $658.8M as of June 30, 2026
Financial Impact
EPS miss of $0.30 vs consensus; revenue in line; net income down 23% YoY
Risk Factors
- Pending Boston Scientific acquisition may not close on expected timeline or at all
- EPS miss signals potential operational or margin pressure beyond acquisition costs
- No guidance removes forward visibility, increasing uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302838410 |
Track record
11 reports on PEN
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +1.63% at T+20 after the May 6, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $321.46 Now $320.62 −0.26% settles Feb 8
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $319.21 Now $320.62 +0.44% settles Feb 4
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Neutral 5/10 Entry $318.95 Now $320.62 +0.52% settles Jan 28
- Jul 30, 202615w ago Press Release Bearish 6/10 Viewing Entry $321.19 to $325.22 Now $320.62 +0.18% ▼ −1.25% +1.20% vs SPY
- May 7, 202627w ago 425 Bullish 7/10 Entry $324.65 to $323.02 Now $320.62 −1.24% ▼ −0.50% −4.34% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $324.65 to $323.02 Now $320.62 +1.24% ▲ +0.50% +4.34% vs SPY
- Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $326.48 to $319.49 Now $320.62 −1.79% ▼ −2.14% −5.25% vs SPY
- Apr 17, 202630w ago 425 Neutral 4/10 Entry $329.71 to $316.73 Now $320.62 −2.76% ▼ −3.94% −10.71% vs SPY
- Apr 1, 202632w ago DEFM14A Bullish 8/10 Entry $330.36 to $315.75 Now $320.62 −2.95% ▼ −4.42% −18.58% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers